Alison Lee (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the background and findings of her presentation entitled: In Utero Household Air Pollution Exposure Is Associated with Reduced Pulmonary Function in Infants (abstract available here).
1. What sort of household air pollution affects pulmonary function in infants? (0:11)
2. Could you tell us a little about the design of your study investigating the effect of household air pollution on lung development in utero? (0:54)
3. What were the findings of this study? (1:43)
4. What are believed to be pathophysiological mechanisms underlying these findings? (2:11)
5. How will these data be used to develop preventative strategies? (2:53)
Speaker disclosure: Alison Lee has nothing to disclose in relation to this video interview.
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Share this Video
Related Videos In Paediatric Respiratory Medicine
Theresa W Guilbert, AAAAI 2023: The VOYAGE study: Impact of exacerbation history on dupilumab efficacy in children with asthma
Dupilumab is indicated as an add-on maintenance treatment in children aged 6 years and older with asthma, and demonstrated clinical efficacy in the pivotal VOYAGE study (NCT0294895). We caught up with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) to discuss the main findings from a post-hoc […]
Theresa W Guilbert, AAAAI 2023: Health and economic burden of asthma exacerbations in children
touchRESPIRATORY were delighted to speak with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) about the health and economic burden of asthma exacerbations in children, and the limitations of current therapeutic options for children with asthma. The abstract ‘Impact Of Exacerbation History On Dupilumab Efficacy In Children […]
Robin Deterding, ERS 2022: Findings from the InPedILD Trial
The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!